<DOC>
	<DOC>NCT00033202</DOC>
	<brief_summary>Gimatecan® is sigma-tau Research's new, potent, oral Topoisomerase I inhibitor. Drugs in this class play a crucial role in destroying DNA replication in tumors. We are conducting this study to determine the Maximum Tolerated Dose of our compound, when given as a capsule, rather than by intravenous injection.</brief_summary>
	<brief_title>This is an Early Study to Investigate the Effect of Gimatecan® in Adults With Solid Tumor</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Inclusion criteria: Histologically/cytologically proven advanced solid tumors Life expectancy of at least 3 months with normal hematological, liver and renal function Exclusion criteria: Pregnant and lactating patients Participation in any investigating drug study within 4 weeks preceding treatment start or concurrent treatment with any other anticancer therapy Gastrointestinal dysfunction that could alter absorption or motility</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Solid Tumor</keyword>
	<keyword>Camptothecin</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>